Venous thromboembolism prevention through the use of novel Factor Xa inhibitors

References

• Wong E, Chaudhry S. Venous thromboembolism (VTE). 2012 Sep 26. cited 2018 Mar 25. http://www.pathophys.org/vte/.
   Google Scholar
• Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. International Journal of Thrombosis and Haemostasis. 2012;10(1):136–144.
   Google Scholar
• Kessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol. 1959;14:943–946.
   PubMed Web of Science ®Google Scholar
• Nicolaides AN, Kakkar VV, Field ES, et al. The origin of deep vein thrombosis: a venographic study. Br J Radiol. 1971;44:653–663. [PubMed] [Cross Ref].
   PubMed Web of Science ®Google Scholar
• Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol. 1974;27:517–528. [PMC free article] [PubMed] [Cross Ref].
   PubMed Web of Science ®Google Scholar
• Paterson JC, McLachlin J. Precipitating factors in venous thrombosis. Surg Gynecol Obstet. 1954;98: 96–102. PubMed.
   PubMedGoogle Scholar
• Hamer JD, Malone PC, Silver IA. The PO2 in venous valve pockets: its possible bearing on thrombogenesis. Br J Surg. 1981;68:166–170. [PubMed] [Cross Ref].
   PubMed Web of Science ®Google Scholar
• Brooks EG, Trotman W, Wadsworth MP, et al. Valves of the deep venous system: an overlooked risk factor. Blood. 2009;114:1276–1279. [PMC free article] [PubMed] [Cross Ref].
   PubMed Web of Science ®Google Scholar
• Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38:1075–1089. [PubMed] [Cross Ref].
   PubMed Web of Science ®Google Scholar
• Closse C, Seigneur M, Renard M, et al. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Thromb Res. 1997;85:159–164. [PubMed] [Cross Ref].
   PubMed Web of Science ®Google Scholar
• Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S–e226S.
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–651. PubMed.
   PubMed Web of Science ®Google Scholar
• Hoffman R, Brenner B. The promise of novel direct oral anticoagulants. Best Pract Res Clin Haematol. 2012;25(3): 351–360. PubMed.
   PubMed Web of Science ®Google Scholar
• Watkins RD, Rondina MT. Review: dOACs do not differ from standard anticoagulants for recurrent VTE; Factor Xa inhibitors reduce bleeding. Ann Intern Med. 2015;163:JC3. PMID 26356595.
   PubMed Web of Science ®Google Scholar
• Bruins Slot KM, Berge E.Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. JAMA. 2014 Mar 19;311(11):1150–1151..
   PubMedGoogle Scholar
• Garland SG, DeRemer CE, Smith SM, et al. Betrixaban: a new oral Factor Xa inhibitor for extended venous thromboembolism prophylaxis in high-risk hospitalized patients. Ann Pharmacother. 2018 Jun;52(6):554–561.
   Web of Science ®Google Scholar
• Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–e736S.
   PubMed Web of Science ®Google Scholar
• Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. Thromb Haemost. 2016 Jun;14(6):1308–1313. Epub 2016 Apr 27. AD Department of Medicine, Division of Hematology-Oncology, University of North Carolina, Chapel Hill, NC, USA. PMID 27299806.
   Web of Science ®Google Scholar
• Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S–e325S.
   PubMed Web of Science ®Google Scholar
• Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S–e277S.
   PubMed Web of Science ®Google Scholar
• Al Yami MS, Kurdi S, Abraham I. Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment. J Blood Med. 2018;9:25–34.
   PubMed Web of Science ®Google Scholar
• Ho KM, Bham E, Pavey W. Incidence of venous thromboembolism and benefits and risks of thromboprophylaxis after cardiac surgery: a systematic review and meta‐analysis. J Am Heart Association: Cardiovasc Cerebrovasc Dis. 2015;4(10):e002652.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
   Web of Science ®Google Scholar
• Depietri L, Marietta M, Scarlini S, et al. Clinical application of application of risk assessment models (Padua Prediction Score and Improve Bleeding Score) on venous thromboembolism, major hemorrhage and health expenditure associated with pharmacologic VTE prophylaxis: a “real life„ prospective and retrospective observational study on patients hospitalized on a Single Internal Medicine Unit (the STIME study). Intern Emerg Med. 2018. DOI:10.1007/s11739-018-1808-z
   PubMedGoogle Scholar
• Arabi Y, Hameed FA, Karen EA, et al., the PREVENT trial group. Statistical analysis plan for the Pneumatic Compression for Preventing Venous Thromboembolism (PREVENT) trial: a study protocol for a randomized controlled trial. Trials. 2018;19:182.
   PubMed Web of Science ®Google Scholar
• Ho KM, Tan JA, Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 128(9):1003–1020.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Alsolamy S, Al-Dawood A, et al. Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial. Trials. 2016 Aug 3;17(1):390. doi:10.1186/s13063-016-1520-0
   Web of Science ®Google Scholar
• Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood. 1984;63(6):1338.
   PubMed Web of Science ®Google Scholar
• Rosing J, van Rijn JL, Bevers EM, et al. The role of activated human platelets in prothrombin and factor X activation. Blood. 1985;65(2):319.
   PubMed Web of Science ®Google Scholar
• Kane WH, Lindhout MJ, Jackson CM, et al. Factor Va-dependent binding of Factor Xa to human platelets. J Biol Chem. 1980;255(3):1170.
   PubMed Web of Science ®Google Scholar
• Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem. 1985;260(4):2119.
   PubMed Web of Science ®Google Scholar
• Lawrence LK, Leung MD. Direct oral anticoagulants and parenteral direct thrombin inhibitors: dosing and adverse effects, UpToDate. Retrieved March 12, 2018. 2018.
   Google Scholar
• Lexicomp Online®, Lexi-Drugs®, Hudson, Ohio: Lexi-Comp, Inc.; March 12, 2018.
   Google Scholar
• Samama MM1. The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thromb Res. 2011 Jun;127(6):497–504. Epub 2010 Oct 2.
   PubMed Web of Science ®Google Scholar
• Kreutz R1. Pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor. Curr Clin Pharmacol. 2014 Feb 9;26(1):75–83.
   PubMedGoogle Scholar
• Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412–421.
   PubMed Web of Science ®Google Scholar
• Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012;72(13):1739.
   PubMed Web of Science ®Google Scholar
• Luettgen JM, Bozarth TA, Bozarth JM, et al. In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable Factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts). 2006;108:4130.
   Web of Science ®Google Scholar
• Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro- 1H-pyrazolo[3, 4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation Factor Xa. J Med Chem. 2007;50:5339–5356.
   PubMed Web of Science ®Google Scholar
• Frost C1, Wang J, Nepal S, et al. Apixaban, an oral, direct Factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013 Feb;75(2):476–487.
   PubMed Web of Science ®Google Scholar
• Morishima Y, Furugohri T, Isobe K, et al. In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct Factor Xa inhibitor, DU-176b. Blood (ASH Annual Meeting Abstracts). 2004;104:1862.
   Web of Science ®Google Scholar
• Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743–753, PubMed
   PubMed Web of Science ®Google Scholar
• Gregory J. Hughes, PharmD, BCPS, CGP and Olga Hilas, PharmD, MPH, BCPS, CGP, FASCP. Edoxaban: investigational Factor Xa inhibitor P. 2014 Oct;39(10):686, 689–690, 715.
   Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al., EINSTEIN investigators. Schellong S oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499. Epub 2010 Dec 3
   PubMed Web of Science ®Google Scholar
• Crowther MA, Cuker A. Reduced-intensity rivaroxaban for the prevention of recurrent venous thromboembolism. N Engl J Med. 2017;376(13):1279–1280. [PubMed 28316277].
   PubMed Web of Science ®Google Scholar
• Kim SM, Moon YW, Lim SJ, et al. Effect of oral Factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thromb Haemost. 2016 Feb;115(3):600–607. Epub 2016 PMID 26790579.
   PubMed Web of Science ®Google Scholar
• Factor Xa inhibitors vs Warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. Bruins Slot, Karsten M. H. MD, PhD 1; Berge, Eivind MD, PhD 1. JAMA. 2014 March 19;311(11):1150–1151.
   PubMedGoogle Scholar
• Culebras A, Messé SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(8):716–724. PubMed 24566225.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013a;368(8):699–708. [PubMed 23216615].
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 ;369:799–808. [PubMed 23808982]
   Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141((2)(suppl)):e419S–e496S. [published correction appears in Chest. 2012; 142(6):1698-1704]. [PubMed 22315268].
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141((2)(suppl)):e419S–e496S. [published correction appears in Chest. 2012;142(6):1698-1704]. [PubMed 22315268].
   PubMed Web of Science ®Google Scholar
• Neumann I, Rada G, Claro JC, et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med. 2012;156(10):710. Epub 2012 Mar 12. 22412038
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141((2) (suppl)):e419S–e496S. PubMed 22315268. [published correction appears in Chest. 2012; 142(6):1698-1704].
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–e267. [PubMed 24682347].
   PubMed Web of Science ®Google Scholar
• Kim SM, Moon YW, Lim SJ, et al. Effect of oral Factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thromb Haemost. 2016 Feb;115(3):600–607. Epub 2016 Jan 21. PMID 26790579.
   PubMed Web of Science ®Google Scholar
• Kim SM, Moon YW, Lim SJ, et al. Park YS Effect of oral Factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thromb Haemost. 2016 Feb;115(3):600–607. Epub 2016 Jan 21. PMID 26790579.
   PubMed Web of Science ®Google Scholar
• Cabral KP, Ansell JE. The role of Factor xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag. 2018 Mar 10;11(2015):117–123. PMC. Web.
   Google Scholar
• Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis.
   Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf (cited 2017 Jun 26).
   Google Scholar
• Gibson CM, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK, Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM, Gold A, Harrington RA, Cohen AT, APEX Investigators. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
   Google Scholar
• EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499–2510. DOI:10.1056/NEJMoa1007903. Epub 2010 Dec 3.
   PubMed Web of Science ®Google Scholar
• Liu X, Johnson M, Mardekian J, et al. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. J Am Heart Assoc. 2015 Dec 1;4(12). pii: e002340.
   PubMed Web of Science ®Google Scholar
• Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406–1415. Epub 2013 Aug 31.
   PubMed Web of Science ®Google Scholar
• Coscia C, Jaureguizar A, Quezada C, et al. Comparison of All-Cause Mortality after Venous Thromboembolism Treatment Between Propensity Score-Adjusted Observational Studies and Matched Randomized Controlled Trials: Meta-Epidemiological Study. Chest. 2018. DOI:10.1016/j.chest2018.10.016.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. for the ROCKET AF Investigators. Rivaroxiban versus Warfarin in Nonvalvular Atrial Fibrillation. Apixaban versus Warfarin in Atrial Fibrillation. N Engl J Med. 2011;365:883–891.
   Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. for the ARISTOTLE Committee and Investigators. Apixaban versus Warfarin in Atrial Fibrillation. N Engl J Med. 2011;365:981–992.
   Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the safety and efficacy of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Cochrane Database Syst Rev. 2013 Aug 8;(8):CD008980. DOI:10.1002/14651858.CD008980.pub2
   PubMedGoogle Scholar
• https://clinicaltrials.gov/ct2/results?term=02157272 ( Accessed on 2016 Jun 06).
   Google Scholar
• Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–977.
   PubMed Web of Science ®Google Scholar
• Medline ® Abstract for Reference. 23 of ‘Direct oral anticoagulants and parenteral direct thrombin inhibitors: dosing and adverse effects’ PubMed TI mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. AU Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M SO J Thromb Haemost. 2015 Nov;13(11):2012–2020. Epub 2015 Oct 5.
   Google Scholar
• Chai-Adisaksopha C, Hillis C, Isayama T, et al. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost. 2015 Nov;13(11):2012–2020. Epub 2015 Oct 5.
   Web of Science ®Google Scholar
• Palladino M, Merli G, Thomson L. Evaluation of the oral direct Factor Xa inhibitor-betrixaban. Expert Opin Investing Drugs. 2013;22(11):1465–1472.
   PubMed Web of Science ®Google Scholar
• Kahale LA, Hakoum MB, Tsolakian IG, et al. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. 2017. DOI:10.1002/14651858.cd006466.pub6.
   Web of Science ®Google Scholar
• Gao J-H, Chu X-C, Wang -L-L, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty. Medicine. 2017;96:40.
   Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902.
   PubMed Web of Science ®Google Scholar